Lupin gets 5 observations from USFDA for its Vizag facility

The inspection of company's Vizag API manufacturing facility by the United States Food and Drug Administration (USFDA) has been completed, Lupin said in a filing to BSE. The inspection was carried out between January 13, 2020 and January 17, 2020, it added. The inspection for the API facility at Vizag closed with five 483 observations, Lupin said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/30uOLoc
via IFTTT